Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.

Naoko HonmaTakamitsu InoueNorihiko TsuchiyaAtsushi KoizumiRyohei YamamotoTaketoshi NaraSohei KandaMingguo HuangKazuyuki NumakuraMitsuru SaitoShintaro NaritaShigeru SatohTomonori Habuchi

Published in: Health science reports (2020)

The initial change in serum PAI-1 level in the early stage of axitinib treatment could be a useful prognostic biomarker in patients with mRCC.

Keyphrases

metastatic renal cell carcinoma
early stage
high throughput
squamous cell carcinoma
sensitive detection
combination therapy
radiation therapy
sentinel lymph node
real time pcr
single cell